(Q45887360)

English

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

0 references

0 references

1 reference

based on heuristic

inferred from title

Steven R. Lentz

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

author name string

M Misgav

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Ozelo

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

S Z Salek

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

D Veljkovic

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Recht

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M Cerqueira

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

B Brand

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

M E Mancuso

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

S Seremetis

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

A Lindblom

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

U Martinowitz

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

publication date

7 May 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

691-697

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Practice patterns in haemophilia A therapy -- global progress towards optimal care

1 reference

https://api.crossref.org/works/10.1111%2FHAE.12159

21 January 2018

Purification and characterization of a new recombinant factor VIII (N8).

1 reference

https://api.crossref.org/works/10.1111%2FHAE.12159

21 January 2018

Functional characteristics of N8, a new recombinant FVIII.

1 reference

https://api.crossref.org/works/10.1111%2FHAE.12159

21 January 2018

Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FHAE.12159

21 January 2018

International comparative field study of N8 evaluating factor VIII assay performance

1 reference

https://api.crossref.org/works/10.1111%2FHAE.12159

21 January 2018

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FHAE.12159

21 January 2018

A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management

1 reference

https://api.crossref.org/works/10.1111%2FHAE.12159

21 January 2018

The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FHAE.12159

21 January 2018

Clinical evaluation of moroctocog alfa (AF-CC), a new generation of B-domain deleted recombinant factor VIII (BDDrFVIII) for treatment of haemophilia A: demonstration of safety, efficacy, and pharmacokinetic equivalence to full-length recombinant fa

1 reference

https://api.crossref.org/works/10.1111%2FHAE.12159

21 January 2018

A postmarketing surveillance study of the safety and efficacy of ReFacto (St Louis-derived active substance) in patients with haemophilia A.

1 reference

https://api.crossref.org/works/10.1111%2FHAE.12159

21 January 2018

Identifiers

10.1111/HAE.12159

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23647704%20AND%20SRC:MED&resulttype=core&format=json

29 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45887360&oldid=1245495095"